Nancy Perrottet

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


25 publications

In press | 2021 | 2020 | 2016 | 2015 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
In press
 
Management strategies of alteplase extravasation.
Fournier A., Riand M., Perrottet N., Sadeghipour F., Pujol E. Neurological sciences. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C1FB2C314ED1]
2021
Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study.
Perrottet N., Fernández-Ruiz M., Binet I., Dickenmann M., Dahdal S., Hadaya K., Müller T., Schaub S., Koller M., Rotman S. et al., 2021. PloS one, 16 (4) pp. e0250829. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8D676A182CA8]
2020
Le bon moment pour un médicament: comment faire passer la pilule ? [The best time for a medication: how to sweeten the pill ?]
Nachar C., Perrottet N., Garnier A., 2020/11/25. Revue medicale suisse, 16 (716) pp. 2254-2258. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_CCA9F1BE39C9]
Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation.
Schwotzer N., Paganetti G., Barchi M., Perrottet N., Aubert V., Sadallah S., Rotman S., Venetz J.P., Matter M., Golshayan D. et al., 2020/07. Xenotransplantation, 27 (4) pp. e12630. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_119F4B750A1D]
Diabète post-transplantation rénale: le point de vue du diabétologue [Post-transplantation diabetes in kidney transplant: from the diabetologist point of view]
Pauchet A., Schwotzer N., Lamine F., Perrottet N., Zanchi A., Golshayan D., Wojtusciszyn A., 2020/06/10. Revue medicale suisse, 16 (697) pp. 1200-1205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_77E6105192BB]
2016
Biases affecting injected doses of an experimental drug during clinical trials.
Perrottet N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2016/07/16. Trials, 17 (1) p. 321. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4D76936AAE9]
 
A retrospective study of deep sternal wound infections: clinical and microbiological characteristics, treatment, and risk factors for complications.
Chan M., Yusuf E., Giulieri S., Perrottet N., Von Segesser L., Borens O., Trampuz A., 2016/03. Diagnostic microbiology and infectious disease, 84 (3) pp. 261-265. Peer-reviewed.
[DOI][Pmid][serval:BIB_B373C099532A]
 
Antifungal activity against planktonic and biofilm Candida albicans in an experimental model of foreign-body infection.
Maiolo E.M., Oliva A., Furustrand Tafin U., Perrotet N., Borens O., Trampuz A., 2016/03. The Journal of infection, 72 (3) pp. 386-392. Peer-reviewed.
[DOI][Pmid][serval:BIB_D9CD5F5F310B]
2015
 
Efficacy and safety of high-dose daptomycin (>6mg/kg) for complicated bone and joint infections and implant-associated infections caused by Gram-positive bacteria.
Perrottet N., Steinrücken J., Chan M., Pannatier A., Borens O., Yusuf E., Trampuz A., 2015. International Journal of Antimicrobial Agents, 46 (4) pp. 480-482. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A2D396DC49BD]
2011
 
Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department
Zingg T., Bez C., Perrottet N., Leung Ki E.L., Pannatier A., Demartines N., 2011. p. 7 dans 98th Annual Congress of the Swiss Society of Surgery, British Journal of Surgery. Peer-reviewed.
[WoS][serval:BIB_A89DAFAF7479]
 
Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of the practice in a surgical ward
Perrottet N., Bez C., Zingg T., Leung Ki E.L., Demartines N., Pannatier A., 2011. p. 435 dans 39th ESCP (European Society of Clinical Pharmacy) European Symposium on Clinical Pharmacy and 13th SFPC (Société Française de Pharmacie Clinique) Congress: Clinical Pharmacy at the Front line of Innovations, International Journal of Clinical Pharmacy.
[WoS][serval:BIB_DA42F7C49330]
2010
 
Ganciclovir exposure under a 450mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Meylan P.R., 2010. Clinical Transplantation, 24 (6) pp. 794-800.
[DOI][WoS][Pmid][serval:BIB_4C94E197C48C]
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet Nancy, Manuel Oriol, Lamoth Frederic, Venetz Jean-Pierre, Sahli Roland, Decosterd Laurent A., Buclin Thierry, Pascual Manuel, Meylan Pascal, 2010. BMC Infectious Diseases, 10 p. 2.
[URN][DOI][WoS][Pmid][serval:BIB_1123642915A2]
2009
 
Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplant recipients: a prospective study : P125
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L., Buclin T., Meylan P., 2009. pp. 32S-33S dans Joint Annual Congress of the Swiss Society for Allergology and Immunology and the Swiss Society for Infectious Diseases, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_80EADAB09A91]
 
Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.
Manuel Oriol, Pascual Manuel, Perrottet Nancy, Lamoth Frederic, Venetz Jean-Pierre, Decosterd Laurent, Buclin Thierry, Meylan Pascal R., 2009. p. 249 dans 9th Joint Meeting of the American Society of Transplant Surgeon and of the American Society of Transplantation, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_18DA47E61C5B]
Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica
Keiser Jennifer, Gruyer Marie-Stella, Perrottet Nancy, Zanolari Boris, Mercier Thomas, Decosterd Laurent, 2009. Journal of Antimicrobial Chemotherapy, 63 (3) pp. 543-549. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E0878357BDA9]
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
[DOI][WoS][Pmid][serval:BIB_6BCA0E0A0A40]
 
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N., Decosterd L.A., Meylan P., Pascual M., Biollaz J., Buclin T., 2009. Clinical Pharmacokinetics, 48 (6) pp. 399-418. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB0583FDF1A4]
2008
 
Disposition of oral valganciclovir during continuous renal replacement therapy in two lung transplant recipients
Perrottet Nancy, Robatel Corinne, Meylan Pascal, Pascual Manuel, Venetz Jean-Pierre, Aubert John-David, Berger Mette M., Decosterd Laurent A., Biollaz Jerome, Buclin Thierry, 2008. p. 566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_90C644532B8E]
 
Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation
Perrottet Nancy, Manuel Oriol, Venetz Jean-Pierre, Lamoth Frederic, Decosterd Laurent A., Buclin Thierry, Biollaz Jerome, Meylan Pascal, Pascual Manuel, 2008. pp. 565-566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
[WoS][serval:BIB_BA42B5399BF1]
2007
 
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples
Perrottet N., Beguin A., Meylan P., Pascual M., Manuel O., Buclin T., Biollaz J., Decosterd L. A., 2007/06. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 852 (1-2) pp. 420-9.
[DOI][WoS][Pmid][serval:BIB_531C59A30064]
 
Pharmacokinetic and pharmacodynamic assessement of valganciclovir in the prophylaxis and treatment of CMV disease in solid organ transplant patients
Manuel O., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2007. pp. 9S dans Annual Conference Swiss Society for Paediatrics, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_28547DFCE2DB]
 
Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique.
Widmer N., Perrottet N., Brunner F., Biollaz J., Buclin T., 2007. pp. 81S dans 75e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_4B9BBCA4E616]
2006
 
Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients
Manuel O., Perrottet N., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2006. pp. S19 dans 12th International Society for infectious Diseases, International Journal of Infectious Diseases. Peer-reviewed.
[WoS][serval:BIB_C405A5C4A4C2]
 
Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique
Widmer N., Perrottet N., Brunner F., Biollaz J., Buclin T., 2006. p. 22 dans Gemeinsamer Kongress der Gesellschaft Schweizerischer Amt- und Spitalapotheker (GSASA) und Schweizerische Gesellschaft für Spitalhygiene (SGS) = Congrès annuel de la Société Suisse des Pharmaciens de l'Administration et des Hôpitaux (GSASA) et de la Société Suisse d'Hygiène Hospitalière (SSHH), GSASA Journal. Peer-reviewed.
[serval:BIB_F2ADD7100F86]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University